183 related articles for article (PubMed ID: 34743198)
1. Risk-stratification of HPV-positive women with low-grade cytology by FAM19A4/miR124-2 methylation and HPV genotyping.
Dick S; Vink FJ; Heideman DAM; Lissenberg-Witte BI; Meijer CJLM; Berkhof J
Br J Cancer; 2022 Feb; 126(2):259-264. PubMed ID: 34743198
[TBL] [Abstract][Full Text] [Related]
2. Long-term CIN3+ risk of HPV positive women after triage with FAM19A4/miR124-2 methylation analysis.
Dick S; Kremer WW; De Strooper LMA; Lissenberg-Witte BI; Steenbergen RDM; Meijer CJLM; Berkhof J; Heideman DAM
Gynecol Oncol; 2019 Aug; 154(2):368-373. PubMed ID: 31182225
[TBL] [Abstract][Full Text] [Related]
3. Validation of the FAM19A4/mir124-2 DNA methylation test for both lavage- and brush-based self-samples to detect cervical (pre)cancer in HPV-positive women.
De Strooper LMA; Verhoef VMJ; Berkhof J; Hesselink AT; de Bruin HME; van Kemenade FJ; Bosgraaf RP; Bekkers RLM; Massuger LFAG; Melchers WJG; Steenbergen RDM; Snijders PJF; Meijer CJLM; Heideman DAM
Gynecol Oncol; 2016 May; 141(2):341-347. PubMed ID: 26921784
[TBL] [Abstract][Full Text] [Related]
4. FAM19A4/miR124-2 methylation analysis as a triage test for HPV-positive women: cross-sectional and longitudinal data from a Dutch screening cohort.
Vink FJ; Lissenberg-Witte BI; Meijer CJLM; Berkhof J; van Kemenade FJ; Siebers AG; Steenbergen RDM; Bleeker MCG; Heideman DAM
Clin Microbiol Infect; 2021 Jan; 27(1):125.e1-125.e6. PubMed ID: 32222459
[TBL] [Abstract][Full Text] [Related]
5. Defining hrHPV genotypes in cervical intraepithelial neoplasia by laser capture microdissection supports reflex triage of self-samples using HPV16/18 and FAM19A4/miR124-2 methylation.
Leeman A; Ebisch RMF; Kasius A; Bosgraaf RP; Jenkins D; van de Sandt MM; de Strooper LMA; Heideman DAM; Snijders PJF; Massuger LFAG; Bekkers RLM; Meijer CJLM; van Kemenade FJ; Quint WGV; Melchers WJG
Gynecol Oncol; 2018 Nov; 151(2):311-318. PubMed ID: 30219239
[TBL] [Abstract][Full Text] [Related]
6. Cervical cancer risk in HPV-positive women after a negative FAM19A4/mir124-2 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow-up.
De Strooper LMA; Berkhof J; Steenbergen RDM; Lissenberg-Witte BI; Snijders PJF; Meijer CJLM; Heideman DAM
Int J Cancer; 2018 Sep; 143(6):1541-1548. PubMed ID: 29663363
[TBL] [Abstract][Full Text] [Related]
7. Methylation markers FAM19A4 and miR124-2 as triage strategy for primary human papillomavirus screen positive women: A large European multicenter study.
Bonde J; Floore A; Ejegod D; Vink FJ; Hesselink A; van de Ven PM; Valenčak AO; Pedersen H; Doorn S; Quint WG; Petry KU; Poljak M; Stanczuk G; Cuschieri K; de Sanjosé S; Bleeker M; Berkhof J; Meijer CJLM; Heideman DAM
Int J Cancer; 2021 Jan; 148(2):396-405. PubMed ID: 32997803
[TBL] [Abstract][Full Text] [Related]
8. Comparing the performance of FAM19A4 methylation analysis, cytology and HPV16/18 genotyping for the detection of cervical (pre)cancer in high-risk HPV-positive women of a gynecologic outpatient population (COMETH study).
Luttmer R; De Strooper LM; Berkhof J; Snijders PJ; Dijkstra MG; Uijterwaal MH; Steenbergen RD; van Kemenade FJ; Rozendaal L; Helmerhorst TJ; Verheijen RH; Ter Harmsel WA; Van Baal WM; Graziosi PG; Quint WG; Heideman DA; Meijer CJ
Int J Cancer; 2016 Feb; 138(4):992-1002. PubMed ID: 26317579
[TBL] [Abstract][Full Text] [Related]
9. Reliable identification of women with CIN3+ using hrHPV genotyping and methylation markers in a cytology-screened referral population.
Leeman A; Del Pino M; Marimon L; Torné A; Ordi J; Ter Harmsel B; Meijer CJLM; Jenkins D; Van Kemenade FJ; Quint WGV
Int J Cancer; 2019 Jan; 144(1):160-168. PubMed ID: 30098013
[TBL] [Abstract][Full Text] [Related]
10. The use of molecular markers for cervical screening of women living with HIV in South Africa.
Kremer WW; van Zummeren M; Breytenbach E; Richter KL; Steenbergen RDM; Meijer CJLM; Dreyer G
AIDS; 2019 Nov; 33(13):2035-2042. PubMed ID: 31385866
[TBL] [Abstract][Full Text] [Related]
11. Triaging HPV-positive, cytology-negative cervical cancer screening results with extended HPV genotyping and p16
Song F; Yan P; Huang X; Wang C; Qu X; Du H; Wu R
BMC Infect Dis; 2021 Apr; 21(1):400. PubMed ID: 33931022
[TBL] [Abstract][Full Text] [Related]
12. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
13. Clinical Regression of High-Grade Cervical Intraepithelial Neoplasia Is Associated With Absence of
Kremer WW; Dick S; Heideman DAM; Steenbergen RDM; Bleeker MCG; Verhoeve HR; van Baal WM; van Trommel N; Kenter GG; Meijer CJLM; Berkhof J
J Clin Oncol; 2022 Sep; 40(26):3037-3046. PubMed ID: 35512257
[TBL] [Abstract][Full Text] [Related]
14. FAM19A4/miR124-2 Methylation Testing and Human Papillomavirus (HPV) 16/18 Genotyping in HPV-Positive Women Under the Age of 30 Years.
Vink FJ; Meijer CJLM; Hesselink AT; Floore AN; Lissenberg-Witte BI; Bonde JH; Pedersen H; Cuschieri K; Bhatia R; Poljak M; Oštrbenk Valenčak A; Hillemanns P; Quint WGV; Del Pino M; Kenter GG; Steenbergen RDM; Heideman DAM; Bleeker MCG
Clin Infect Dis; 2023 Feb; 76(3):e827-e834. PubMed ID: 35686306
[TBL] [Abstract][Full Text] [Related]
15. Expression of p16 and HPV E4 on biopsy samples and methylation of FAM19A4 and miR124-2 on cervical cytology samples in the classification of cervical squamous intraepithelial lesions.
Leeman A; Jenkins D; Del Pino M; Ordi J; Torné A; Doorbar J; Meijer CJLM; van Kemenade FJ; Quint WGV
Cancer Med; 2020 Apr; 9(7):2454-2461. PubMed ID: 32022461
[TBL] [Abstract][Full Text] [Related]
16. Performance of HPV Genotyping Combined with p16/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women.
Jiang MY; Wu Z; Li T; Yu L; Zhang SK; Zhang X; Qu P; Sun P; Xi MR; Liu X; Liao G; Sun L; Zhang Y; Chen W; Qiao YL
Cancer Prev Res (Phila); 2020 Feb; 13(2):163-172. PubMed ID: 31871224
[TBL] [Abstract][Full Text] [Related]
17. Risk stratification of HPV-positive results using extended genotyping and cytology: Data from the baseline phase of the Onclarity trial.
Stoler MH; Parvu V; Yanson K; Andrews J; Vaughan L
Gynecol Oncol; 2023 Jul; 174():68-75. PubMed ID: 37149907
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status].
Luo HX; Du H; Liu ZH; Zhang LJ; Wang C; Wu RF
Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):232-238. PubMed ID: 29575846
[No Abstract] [Full Text] [Related]
19. HPV genotyping for triage of women with abnormal cervical cancer screening results: a multicenter prospective study.
Nakamura Y; Matsumoto K; Satoh T; Nishide K; Nozue A; Shimabukuro K; Endo S; Nagai K; Oki A; Ochi H; Morishita Y; Noguchi M; Yoshikawa H
Int J Clin Oncol; 2015 Oct; 20(5):974-81. PubMed ID: 25652908
[TBL] [Abstract][Full Text] [Related]
20. Triage options to manage high-risk human papillomavirus-positive women: A population-based cross-sectional study from rural China.
Rezhake R; Chen F; Hu SY; Zhao XL; Zhang X; Cao J; Qiao YL; Zhao FH; Arbyn M
Int J Cancer; 2020 Oct; 147(8):2053-2064. PubMed ID: 32249409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
